What is the long-term survival benefit of radiofrequency ablation in patients with colorectal liver metastases?

2008 ◽  
Vol 5 (5) ◽  
pp. 246-247
Author(s):  
Riccardo Lencioni
2016 ◽  
Vol 23 (6) ◽  
pp. 1897-1905 ◽  
Author(s):  
Isamu Hosokawa ◽  
Marc-Antoine Allard ◽  
Maximiliano Gelli ◽  
Oriana Ciacio ◽  
Eric Vibert ◽  
...  

2017 ◽  
Vol 24 (S3) ◽  
pp. 655-655
Author(s):  
Alessandro Cucchetti ◽  
Matteo Cescon ◽  
Valentina Bertuzzo ◽  
Giorgio Ercolani

2007 ◽  
Vol 48 (3) ◽  
pp. 253-258 ◽  
Author(s):  
S. M. Sørensen ◽  
F. V. Mortensen ◽  
D. T. Nielsen

2017 ◽  
Vol 24 (S3) ◽  
pp. 656-657
Author(s):  
Isamu Hosokawa ◽  
Marc-Antoine Allard ◽  
Gabriella Pittau ◽  
Masaru Miyazaki ◽  
René Adam

2008 ◽  
Vol 49 (1) ◽  
pp. 21-21 ◽  
Author(s):  
D. T. Nielsen ◽  
S. M. Sørensen ◽  
F. V. Mortensen

2021 ◽  
pp. 67-72
Author(s):  
Sung Jin Oh

Liver metastasis from gastric cancer has a very poor prognosis. Herein, we present two cases of liver metastases (synchronous and metachronous) from advanced gastric cancer. In the first case, the patient underwent radical subtotal gastrectomy. Liver metastases occurred 6 months after surgery while the patient was receiving adjuvant chemotherapy, but two hepatic tumors were successfully removed by radiofrequency ablation (RFA). In the second case, liver metastases occurred 15 months after surgery for gastric cancer. The patient also received RFA for one hepatic tumor, and other suspicious metastatic tumors were treated with systemic chemotherapy. Although these case presentations are limited for the efficacy of RFA treatment with systemic chemotherapy for hepatic metastases from gastric cancer, our findings showed long-term survival (overall survival for 108 and 67 months, respectively) of the affected patients, without recurrence. Therefore, we suggest that RFA treatment with systemic chemotherapy could be an effective alternative treatment modality for hepatic metastases from gastric cancer.


Sign in / Sign up

Export Citation Format

Share Document